Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company announced on Saturday that it has updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in earlier untreated PD-L1-selected NSCLC without sensitising mutations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
IBI939, an IgG4k recombinant fully human anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) monoclonal antibody, has been developed by Innovent Biologics.
This Phase 1b study is intended to assess safety, tolerability, and efficacy of combination therapy of IBI939 with sintilimab in subjects with previously untreated, locally advanced unresectable or metastatic PD-L1 TPS greater than or equal to 50 NSCLC without sensitising mutations (clinicalTrials.gov, NCT04672369).
Effective 1 January 2023, 42 pts were randomised (2:1) to receive IBI939 and sintilimab (experimental arm, n=28) or sintilimab monotherapy (control arm, n=14).
The study results revealed median progression free survival (PFS) follow-up of 12.2 months in the experimental arm and 11.3 months in the control arm, respectively, median PFS per investigator was 13.2 months (95% CI: 6.7-16.5) and 6.4 months (95% CI: 1.4-NA), and the hazard ratio (HR) between two arms was 0.62. It also indicated that 96.4% of subjects in the experimental arm and 71.4% of subjects in the control arm experienced treatment-related adverse event (TRAE). Each arm occurred one treatment-emergent adverse event (TEAE) resulting in the end of treatment, and no TEAE leading to death occurred in the experimental arm.
Outcome from this updated evaluation following longer follow-up indicated that IBI939 plus sintilimab combination therapy had continued efficacy and manageable safety profile in previously untreated PD-L1 TPS greater than or equal to 50% NSCLC without sensitising mutations.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study